Skip to main content
Shenzhen Salubris Pharmaceuticals Co., Ltd. logo

Shenzhen Salubris Pharmaceuticals Co., Ltd. — Investor Relations & Filings

Ticker · 002294 ISIN · CNE100000FW8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,658 across all filing types
Latest filing 2015-03-24 Audit Report / Informat…
Country CN China
Listing Shenzhen Stock Exchange 002294

About Shenzhen Salubris Pharmaceuticals Co., Ltd.

https://www.salubris.com

Shenzhen Salubris Pharmaceuticals Co., Ltd. is a research-driven enterprise focused on the development, manufacturing, and commercialization of innovative drugs and medical devices. The company specializes in therapeutic areas including cardiovascular diseases, chronic kidney disease, and metabolic disorders. Its product portfolio features proprietary treatments such as Allisartan Isoproxil for hypertension and Clopidogrel Bisulfate for anti-platelet therapy. Salubris maintains an integrated value chain encompassing research and development, active pharmaceutical ingredient production, and finished dosage manufacturing. The firm emphasizes innovation through its dedicated R&D centers and strategic focus on biologics and small molecule drugs, aiming to provide comprehensive clinical solutions for chronic conditions.

Recent filings

Filing Released Lang Actions
关于公司募集资金年度存放与实际使用情况的鉴证报告
Audit Report / Information Classification · 95% confidence The document is titled as a "鉴证报告" (Assurance Report) on the "募集资金年度存放与实际使用情况" (Annual Deposit and Actual Use of Raised Funds) for Shenzhen Salubris Pharmaceuticals Co., Ltd. It references regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange regarding the management and use of raised funds. The document includes detailed financial data on the raised funds, their usage, balances, and compliance with regulatory requirements. It is prepared by an accounting firm providing an assurance opinion on the board's special report about the raised funds. This type of document is a standalone audit or assurance report focused on a specific regulatory requirement related to raised funds, not a full annual report or interim report. It is not a simple announcement or certification but contains substantive financial and compliance information. Therefore, it fits the category of an Audit Report / Information (AR). The document length (9,328 characters) and detailed content confirm it is a full report, not just an announcement. FY 2014
2015-03-24 Chinese
2014年度内部控制自我评价报告
Audit Report / Information Classification · 95% confidence The document is titled '2014 年度内部控制自我评价报告' which translates to '2014 Annual Internal Control Self-Evaluation Report'. It discusses the company's internal control evaluation for the year ending December 31, 2014, including the scope, standards, and conclusions about internal control effectiveness. The content focuses on internal control assessment rather than full financial statements or comprehensive annual performance. It is a standalone report on internal control evaluation, not a full annual report (10-K) or audit report (AR). It is not an announcement or certification but a substantive report on internal controls. Therefore, it fits best under Audit Report / Information (AR), which includes internal control reports and related audit information excluding full annual reports. FY 2014
2015-03-24 Chinese
2014年年度报告
Annual Report Classification · 100% confidence The document is titled as the "2014 年年度报告全文" which translates to "2014 Annual Report Full Text" for Shenzhen Salubris Pharmaceuticals Co., Ltd. It contains detailed sections typical of an annual report, including company overview, financial data and indicators, board of directors report, risk disclosures, accounting policies, financial statements, and other comprehensive information. The document length is about 15,000 characters, indicating it is a full report rather than a brief announcement. It includes audited financial data, management discussion, and detailed operational and financial analysis for the fiscal year 2014. There is no indication that this is merely an announcement or a certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2014
2015-03-24 Chinese
独立董事候选人声明（何素英）
Board/Management Information Classification · 95% confidence The document is a detailed declaration by an independent director candidate of Shenzhen Xinlitai Pharmaceutical Co., Ltd. It contains statements about the candidate's qualifications, independence, compliance with regulatory requirements, and absence of conflicts of interest. There is no financial data, no report of financial results, no voting results, no management changes, and no mention of any meeting or report publication. The document is a formal declaration related to board/management information, specifically concerning the appointment or candidacy of an independent director. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length is 4638 characters, which is consistent with a detailed declaration rather than a brief announcement or a full report.
2015-03-24 Chinese
招商证券股份有限公司关于公司2014年度募集资金存放与使用情况专项核查报告
Audit Report / Information Classification · 95% confidence The document is a detailed report from 招商证券股份有限公司 (China Merchants Securities Co., Ltd.) acting as the sponsor for 深圳信立泰药业股份有限公司 (Shenzhen Salubris Pharmaceuticals Co., Ltd.) regarding the 2014 annual special audit on the deposit and use of raised funds. It includes detailed financial data on the raised funds, their usage, bank account balances, project investment progress, changes in project locations and methods, and compliance with regulatory requirements. The document references specific regulatory guidelines from the China Securities Regulatory Commission and Shenzhen Stock Exchange, and it is a standalone audit report focusing on the use and management of raised funds for the year 2014. It is not an annual report, earnings release, or a simple announcement. The length (7739 characters) and content indicate it is a full report, not just an announcement of a report. Therefore, it fits the definition of an Audit Report / Information (AR). FY 2014
2015-03-24 Chinese
2014年度募集资金存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is titled as a "2014年度募集资金存放与使用情况的专项报告" which translates to "Special Report on the Deposit and Use of Raised Funds for the Year 2014". It details the amount of funds raised, their usage, balances, management, and changes in investment projects related to the raised capital. The content focuses on the management and use of funds raised through public issuance, including detailed tables of fund usage, project progress, and compliance with regulatory requirements. There is no indication that this is a full annual report, audit report, or earnings release. Instead, it is a specialized report on the use of capital raised by the company, which aligns with the category of Capital/Financing Update (CAP). The document is substantive and not merely an announcement or certification, so it is not RPA or RNS. Therefore, the best fitting classification is CAP.
2015-03-24 Chinese

Browse filings by year

18 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.